Viiv Hlthcare Drug Patent Portfolio

Viiv Hlthcare owns 18 orange book drugs protected by 43 US patents with Rescriptor having the least patent protection, holding only 2 patents. And Juluca with maximum patent protection, holding 11 patents. Given below is the list of Viiv Hlthcare's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12011506 Combination and uses and treatments thereof 05 Sep, 2038
Active
US11224597 Pharmaceutical compositions 15 Sep, 2031
Active
US11234985 Antiviral therapy 24 Jan, 2031
Active
US10426780 Antiviral therapy 24 Jan, 2031
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
Active
US8168615 Prodrugs of piperazine and substituted piperidine antiviral agents 13 Jul, 2029
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
Active
US7745625 Prodrugs of piperazine and substituted piperidine antiviral agents 19 Nov, 2027
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
Active
US11389447 Aqueous suspensions of TMC278 30 Jun, 2027
Active
US10927129 N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity 28 Apr, 2026
Active
US8410103 (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent 28 Apr, 2026
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
Active
US8461333 Salts of prodrugs of piperazine and substituted piperidine antiviral agents 25 Feb, 2025
Active
US7368460 Tropane derivatives useful in therapy 25 May, 2023 Expired
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023 Expired
US7368460 Tropane derivatives useful in therapy 25 Nov, 2022 Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022 Expired
US6667314 Tropane derivatives useful in therapy 06 Feb, 2022 Expired
US7576097 Tropane derivatives useful in therapy 25 Nov, 2021 Expired
US6667314 Tropane derivatives useful in therapy 06 Aug, 2021 Expired
US7576097 Tropane derivatives useful in therapy 25 May, 2021 Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021 Expired
US6514953 Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate 15 Jan, 2020 Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019 Expired
US6586430 CCR5 modulators 01 Dec, 2019 Expired
US6641843 Pharmaceutical compositions 04 Aug, 2019 Expired
US6514953 Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate 15 Jul, 2019 Expired
US6177101 Delavirdine high strength tablet formulation 07 Jun, 2019 Expired
US6641843 Pharmaceutical compositions 04 Feb, 2019 Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 Nov, 2018 Expired
US6004968 Pharmaceutical compositions containing lamivudine 20 Sep, 2018 Expired
US6436989 Prodrugs of aspartyl protease inhibitors 24 Jun, 2018 Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 May, 2018 Expired
US6004968 Pharmaceutical compositions containing lamivudine 20 Mar, 2018 Expired
US6436989 Prodrugs of aspartyl protease inhibitors 24 Dec, 2017 Expired
US5905082 Crystalline oxathiolane derivatives 18 Nov, 2016 Expired
US6417191 Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Sep, 2016 Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016 Expired
US6417191 Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Mar, 2016 Expired
US5563142 Diaromatic substituted compounds as anti-HIV-1 agents 08 Oct, 2013 Expired
US5859021 Antiviral combinations 15 Nov, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Viiv Hlthcare.

Activity Date Patent Number
Patent litigations
Email Notification 28 May, 2024 US11389447
Mail Patent eCofC Notification 28 May, 2024 US11389447
Patent eCofC Notification 28 May, 2024 US11389447
Recordation of Patent eCertificate of Correction 28 May, 2024 US11389447
Email Notification 23 Apr, 2024 US11389447
Mail Pub Notice re 312 amendment 23 Apr, 2024 US11389447
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 18 Apr, 2024 US11389447
Patent Term Extension Certificate 11 Mar, 2024 US8168615
transaction for FDA Determination of Regulatory Review Period 25 Jan, 2024 US8410103
transaction for FDA Determination of Regulatory Review Period 25 Jan, 2024 US8410103
Expire Patent 22 Jan, 2024 US8080551
Expire Patent 22 Jan, 2024 US8080551
Payment of Maintenance Fee, 12th Year, Large Entity 19 Oct, 2023 US8168615
Notice of Final Determination -Eligible 03 Oct, 2023 US8168615
Payment of Maintenance Fee, 12th Year, Large Entity 23 Aug, 2023 US8129385


Viiv Hlthcare's Drug Patent Litigations

Viiv Hlthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2012, against patent number US6436989. The petitioner Ranbaxy Laboratories Ltd. et al., challenged the validity of this patent, with Vertex Pharmaceuticals Incorporated as the respondent. Click below to track the latest information on how companies are challenging Viiv Hlthcare's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11389447 October, 2020 Decision
(02 Aug, 2021)
JANSSEN SCIENCES IRELAND UC
US6436989 February, 2016 FWD Entered
(28 Jul, 2017)
Vertex Pharmaceuticals Incorporated Lupin Limited
US6436989 December, 2014 Terminated-Settled
(03 Nov, 2015)
Vertex Pharmaceuticals Incorporated Lupin Limited
US6417191 June, 2014 Terminated-Settled
(03 Aug, 2015)
ViiV Healthcare Co. Apotex Corp.
US6417191 January, 2015 Terminated-Denied
(25 Jun, 2015)
ViiV Healthcare Co. Teva Pharmaceuticals USA, Inc.
US6436989 October, 2012 Terminated-Settled
(15 Nov, 2013)
Vertex Pharmaceuticals Incorporated Ranbaxy Laboratories Ltd. et al.


Viiv Hlthcare Drug Patents' Oppositions Filed in EPO

Viiv Hlthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17195280A Feb, 2020 Gilead Sciences, Inc. Opposition rejected
EP16187411A May, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP16187411A May, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP16187411A May, 2019 Sandoz AG Granted and Under Opposition
EP16187411A May, 2019 Cooke, Richard Granted and Under Opposition
EP15164931A Dec, 2018 Cooke, Richard Granted and Under Opposition
EP15164931A Dec, 2018 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP16154531A Dec, 2018 Gilead Sciences, Inc. Patent maintained as amended
EP07786802A Oct, 2018 HGF Limited Opposition rejected
EP06822311A Nov, 2016 Zwicker Schnappauf & Partner PartG mbB Opposition procedure closed
EP11737484A Feb, 2016 Page White & Farrer Limited Revoked
EP11737484A Feb, 2016 LEK Pharmaceuticals d.d. Revoked
EP11737484A Feb, 2016 Ter Meer Steinmeister & Partner Patentanwälte mbB Revoked
EP11737484A Feb, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP04787096A Jan, 2016 Page White & Farrer Limited Patent maintained as amended
EP06758843A May, 2014 Ahrens, Gabriele Opposition procedure closed
EP05108086A Feb, 2012 Hamm, Volker The patent has been limited


Viiv Hlthcare's Family Patents

Viiv Hlthcare drugs have patent protection in a total of 69 countries. It's US patent count contributes only to 15.4% of its total global patent coverage. 20 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Viiv Hlthcare Drug List

Given below is the complete list of Viiv Hlthcare's drugs and the patents protecting them.


1. Apretude

Apretude is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11224597 Pharmaceutical compositions 15 Sep, 2031
(6 years from now)
Active
US10927129 N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity 28 Apr, 2026
(1 year, 4 months from now)
Active
US8410103 (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent 28 Apr, 2026
(1 year, 4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apretude's drug page


2. Cabenuva Kit

Cabenuva Kit is protected by 7 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11224597 Pharmaceutical compositions 15 Sep, 2031
(6 years from now)
Active
US11389447 Aqueous suspensions of TMC278 30 Jun, 2027
(2 years from now)
Active
US10927129 N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity 28 Apr, 2026
(1 year, 4 months from now)
Active
US8410103 (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent 28 Apr, 2026
(1 year, 4 months from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(4 months from now)
Active
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023
(1 year, 8 months ago)
Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cabenuva Kit's drug page


3. Combivir

Combivir is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5905082
(Pediatric)
Crystalline oxathiolane derivatives 18 Nov, 2016
(8 years ago)
Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016
(8 years ago)
Expired
US5859021
(Pediatric)
Antiviral combinations 15 Nov, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivir's drug page


4. Dovato

Dovato is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11234985 Antiviral therapy 24 Jan, 2031
(6 years from now)
Active
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dovato's drug page


5. Epivir

Epivir is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6004968
(Pediatric)
Pharmaceutical compositions containing lamivudine 20 Sep, 2018
(6 years ago)
Expired
US6004968 Pharmaceutical compositions containing lamivudine 20 Mar, 2018
(6 years ago)
Expired
US5905082
(Pediatric)
Crystalline oxathiolane derivatives 18 Nov, 2016
(8 years ago)
Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epivir's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Epzicom

Epzicom is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6294540
(Pediatric)
Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 Nov, 2018
(6 years ago)
Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 May, 2018
(6 years ago)
Expired
US5905082
(Pediatric)
Crystalline oxathiolane derivatives 18 Nov, 2016
(8 years ago)
Expired
US6417191
(Pediatric)
Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Sep, 2016
(8 years ago)
Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016
(8 years ago)
Expired
US6417191 Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Mar, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epzicom's drug page


7. Juluca

Juluca is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12011506 Combination and uses and treatments thereof 05 Sep, 2038
(13 years from now)
Active
US10426780 Antiviral therapy 24 Jan, 2031
(6 years from now)
Active
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(4 months from now)
Active
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023
(1 year, 8 months ago)
Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022
(2 years ago)
Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021
(3 years ago)
Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juluca's drug page


8. Lexiva

Lexiva is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6514953
(Pediatric)
Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate 15 Jan, 2020
(4 years ago)
Expired
US6514953 Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate 15 Jul, 2019
(5 years ago)
Expired
US6436989
(Pediatric)
Prodrugs of aspartyl protease inhibitors 24 Jun, 2018
(6 years ago)
Expired
US6436989 Prodrugs of aspartyl protease inhibitors 24 Dec, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexiva's drug page


9. Rescriptor

Rescriptor is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6177101 Delavirdine high strength tablet formulation 07 Jun, 2019
(5 years ago)
Expired
US5563142 Diaromatic substituted compounds as anti-HIV-1 agents 08 Oct, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rescriptor's drug page


10. Rukobia

Rukobia is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8168615 Prodrugs of piperazine and substituted piperidine antiviral agents 13 Jul, 2029
(4 years from now)
Active
US7745625 Prodrugs of piperazine and substituted piperidine antiviral agents 19 Nov, 2027
(2 years from now)
Active
US8461333 Salts of prodrugs of piperazine and substituted piperidine antiviral agents 25 Feb, 2025
(2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rukobia's drug page


11. Selzentry

Selzentry is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7368460
(Pediatric)
Tropane derivatives useful in therapy 25 May, 2023
(1 year, 6 months ago)
Expired
US7368460 Tropane derivatives useful in therapy 25 Nov, 2022
(2 years ago)
Expired
US6667314
(Pediatric)
Tropane derivatives useful in therapy 06 Feb, 2022
(2 years ago)
Expired
US7576097
(Pediatric)
Tropane derivatives useful in therapy 25 Nov, 2021
(3 years ago)
Expired
US6667314 Tropane derivatives useful in therapy 06 Aug, 2021
(3 years ago)
Expired
US7576097 Tropane derivatives useful in therapy 25 May, 2021
(3 years ago)
Expired
US6586430 CCR5 modulators 01 Dec, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Selzentry's drug page


12. Tivicay

Tivicay is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tivicay's drug page


13. Tivicay Pd

Tivicay Pd is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tivicay Pd's drug page


14. Triumeq

Triumeq is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active
US6294540
(Pediatric)
Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 Nov, 2018
(6 years ago)
Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 May, 2018
(6 years ago)
Expired
US5905082
(Pediatric)
Crystalline oxathiolane derivatives 18 Nov, 2016
(8 years ago)
Expired
US6417191
(Pediatric)
Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Sep, 2016
(8 years ago)
Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016
(8 years ago)
Expired
US6417191 Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Mar, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triumeq's drug page


15. Triumeq Pd

Triumeq Pd is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9242986
(Pediatric)
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Jun, 2030
(5 years from now)
Active
US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates 08 Dec, 2029
(4 years from now)
Active
US8129385
(Pediatric)
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Apr, 2028
(3 years from now)
Active
US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 05 Oct, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triumeq Pd's drug page


16. Trizivir

Trizivir is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6294540
(Pediatric)
Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 Nov, 2018
(6 years ago)
Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 May, 2018
(6 years ago)
Expired
US5905082
(Pediatric)
Crystalline oxathiolane derivatives 18 Nov, 2016
(8 years ago)
Expired
US6417191
(Pediatric)
Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Sep, 2016
(8 years ago)
Expired
US5905082 Crystalline oxathiolane derivatives 18 May, 2016
(8 years ago)
Expired
US6417191 Synergistic combinations of zidovudine, 1592U89 and 3TC 28 Mar, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trizivir's drug page


17. Vocabria

Vocabria is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10927129 N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity 28 Apr, 2026
(1 year, 4 months from now)
Active
US8410103 (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent 28 Apr, 2026
(1 year, 4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vocabria's drug page


18. Ziagen

Ziagen is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6641843
(Pediatric)
Pharmaceutical compositions 04 Aug, 2019
(5 years ago)
Expired
US6641843 Pharmaceutical compositions 04 Feb, 2019
(5 years ago)
Expired
US6294540
(Pediatric)
Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 Nov, 2018
(6 years ago)
Expired
US6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections 14 May, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ziagen's drug page